Taurine attenuated methotrexate-induced intestinal injury by regulating NF-κB/iNOS and Keap1/Nrf2/HO-1 signals

Hassanein, Emad H.M.; Althagafy, Hanan S.; Atwa, Ahmed M.; Kozman, Magy R.; El-Sayed, Mohamed.I. Kotb; Soubh, Ayman A.

doi:10.1016/j.lfs.2022.121180

Cited by 9 publications

(6 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the protective effects on intestinal integrity, inflammation and oxidative stress were also found for other amino acids including serine, 46,47 tryptophan [48][49][50] and taurine. [51][52][53] Relative to age-matched CON mice, therefore, lower levels of these amino acids in the jejunum of T1D mice may indicate jejunum dysfunction, affecting the onset and progression of diabetes and its complications.…”

Section: Discussionmentioning

confidence: 99%

Untargeted metabolomics analysis reveals spatial metabolic heterogeneity in different intestinal segments of type 1 diabetic mice

Gong,

Chen,

Yin

et al. 2024

Mol. Omics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Untargeted metabolomics analysis reveals spatial metabolic heterogeneity in different intestinal segments of type 1 diabetic mice

Gong,

Chen,

Yin

et al. 2024

Mol. Omics

View full text Add to dashboard Cite

show abstract

“…The KEAP1 is a substrate‐recognizing subunit of cullin RING ligase (CRL), responsible for ubiquitylation and subsequent degradation of antioxidant transcription factor nuclear factor erythroid 2‐related factor 2 (Nrf2) 26,386–389 . Structurally, KEAP1 mainly consists of an N‐terminal bric‐a‐brac of tramtrack, a broad complex (BTB) domain for cullin 3 binding, and a C‐terminal Kelch domain for substrate recruitment 390–393 . Recently, a number of small molecules have been shown to modulate the KEAP1/NRF2 axis (Figure 6).…”

Section: Keap1 Ligands and Their Utilizations In Protacsmentioning

confidence: 99%

“… 26 , 386 , 387 , 388 , 389 Structurally, KEAP1 mainly consists of an N‐terminal bric‐a‐brac of tramtrack, a broad complex (BTB) domain for cullin 3 binding, and a C‐terminal Kelch domain for substrate recruitment. 390 , 391 , 392 , 393 Recently, a number of small molecules have been shown to modulate the KEAP1/NRF2 axis (Figure 6 ). 284 , 394 , 395 , 396 , 397 , 398 The BTB domain inhibitors, including natural products KEAP1‐1 (a semi‐synthetic oleanolic acid derivative bardoxolone) and KEAP1‐2 (piperlongumine), were discovered as a promising NRF2 modulators utilized in TPD applications by covalently interacting with cysteine residues of KEAP1.…”

Section: Keap1 Ligands and Their Utilizations In Protacsmentioning

confidence: 99%

PROTACs: A novel strategy for cancer drug discovery and development

Han

Sun

2023

MedComm

View full text Add to dashboard Cite

Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists of three components: a small molecule that binds to a target protein, an E3 ligase ligand (consisting of an E3 ligase and its small molecule recruiter), and a chemical linker that hooks first two components together. In the past 20 years, we have witnessed advancement of multiple PRO-TAC degraders into the clinical trials for anticancer therapies. However, one of the major challenges of PROTAC technology is that only very limited number of E3 ligase recruiters are currently available as E3 ligand for targeted protein degradation (TPD), although human genome encodes more than 600 E3 ligases. Thus, there is an urgent need to identify additional effective E3 ligase recruiters for TPD applications. In this review, we summarized the existing RING-type E3 ubiquitin ligase and their small molecule recruiters that act as effective E3 ligands of PRO-TAC degraders and their application in anticancer drug discovery. We believe that this review could serve as a reference in future development of efficient E3 ligands of PROTAC technology for cancer drug discovery and development.

show abstract

“…Multiple factors are associated with the progression of endometrial diseases 12–14 . In addition, the Keap1/Nrf2/HO‐1 pathway has been implicated in several diseases 15,16 . Zborowski et al 15 suggested that the Keap1/Nrf2/HO‐1 signaling pathway contributes to the antidepressant‐like action of p ‐chlorodiphenyl diselenide in diabetic mice 15 .…”

Section: Introductionmentioning

confidence: 99%

Oxycodone alleviates mifepristone‐stimulated human endometrial stromal cell injury by activating the Keap1/Nrf2/HO‐1 signaling pathway

Zhu,

Yao,

Shen

2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

BackgroundEndometrial injury is a common disease in women caused by intrauterine inflammation, infections, and endocrine disorders. Human endometrial stromal cells (hEndoSCs) can maintain endometrial homeostasis and play an important role in repairing endometrial injury. Mifepristone, a steroidal anti‐progesterone drug, is widely used in the field of reproductive medicine worldwide. Mifepristone‐induced hEndoSC injury has been used to study endometrial injury in vitro. At present, the pathogenesis and potential regulatory mechanisms of oxycodone in endometrial injury remain unknown.AimsWe aimed to evaluate the functions of oxycodone in mifepristone‐stimulated hEndoSC injury and analyze its potential molecular mechanism.Materials & MethodshEndoSC viability, cytotoxicity, and apoptosis were analyzed using the methyl thiazolyl tetrazolium assay, the lactate dehydrogenase assay, and flow cytometry, respectively. Furthermore, the levels of cleaved‐Caspase3, Keap1, Nrf2, HO‐1, and NQO1 were assessed using reverse transcription quantitative polymerase chain reaction and western blot analysis, and the release of inflammatory cytokines was determined using the enzyme‐linked immunosorbent assay.ResultsWe observed that oxycodone had no adverse effects on hEndoSCs; rather, it protected hEndoSCs against mifepristone‐induced endometrial damage, as confirmed by the enhanced cell viability, reduced number of apoptotic cells, decreased Caspase3 activity and inflammatory cytokine secretion, and increased Keap1/Nrf2/HO‐1 pathway‐related protein expression. In addition, we found that the protective effects of oxycodone on mifepristone‐induced hEndoSC injury were inhibited by ML385 (a Keap1/Nrf2/HO‐1 inhibitor).ConclusionIn summary, we confirmed that oxycodone alleviates mifepristone‐induced hEndoSC injury by activating the Keap1/Nrf2/HO‐1 signaling pathway.

show abstract

Taurine attenuated methotrexate-induced intestinal injury by regulating NF-κB/iNOS and Keap1/Nrf2/HO-1 signals

Cited by 9 publications

References 66 publications

Untargeted metabolomics analysis reveals spatial metabolic heterogeneity in different intestinal segments of type 1 diabetic mice

Untargeted metabolomics analysis reveals spatial metabolic heterogeneity in different intestinal segments of type 1 diabetic mice

PROTACs: A novel strategy for cancer drug discovery and development

Oxycodone alleviates mifepristone‐stimulated human endometrial stromal cell injury by activating the Keap1/Nrf2/HO‐1 signaling pathway

Contact Info

Product

Resources

About